Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Summary of Components of Marketable Securities

The following is a summary of the components of our marketable debt securities and the underlying fair value input level tier hierarchy (see fair value of financial instruments) (in thousands):

	As of December 31, 2022
	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
U.S. government obligations	$	1484	$	6	$	(12)	$	1478
Corporate obligations	5,702		1,228		(80)		6,850
	$	7,186	$	1,234	$	(92)	$	8,328

	As of December 31, 2021
	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
U.S. government obligations	$	650	$	17	$	—	$	667
Corporate obligations	8,304		—		(192)		8,112
	$	8,954	$	17	$	(192)	$	8,779

Schedule of Accounts Receivable Net

Accounts are written off as uncollectible at the time we determine that collections are unlikely. Accounts receivable, net is comprised of the following (in thousands):

	December 31, 2022		December 31, 2021
Trade accounts receivable	$	37,568	$	18,520
Unbilled accounts receivable	2,626		23,089
	40,194		41,609
Less allowances	(3,140)		(3,901)
Total accounts receivable	$	37,054	$	37,708

Schedule of Components of Inventory

At December 31, 2022 and 2021, the components of inventory are as follows (in thousands):

	December 31, 2022		December 31, 2021
Diagnostic services testing material	$	1,739	$	2,989
Raw materials	1,639		1,514
Work in process	754		260
Finished goods	356		272
Inventory	$	4,488	$	5,035
Inventory valuation reserve	(512)		(435)
Inventory, net	$	3,976	$	4,600

Schedule of Fair Value of Financial Instruments

	As of December 31, 2022
	Level 1		Level 2		Level 3		Total
U.S. government obligations	$	—	$	1,478	$	—	$	1,478
Corporate obligations	5,497		1,354		—		6,851
	$	5,497	$	2,832	$	—	$	8,329

	As of December 31, 2021
	Level 1		Level 2		Level 3		Total
U.S. government obligations	$	—	$	667	$	—	$	667
Corporate obligations	—		8,112		—		8,112
Marketable equity securities	76		—		—		76
	$	76	$	8,779	$	—	$	8,855

Schedule of Disaggregation of Deferred Revenue

The following table disaggregates our deferred revenue by recognition period (in thousands):

	As of December 31, 2022		As of December 31, 2021
Recognition Period
0-12 Months	$	2,499	$	2,034
13-24 Months	683		530
Over 24 Months	376		375
Total	$	3,558	$	2,939

The following table disaggregates the Company’s revenue by revenue source for Fiscal 2022 and 2021 (in thousands):

	For the years ended
Revenue by Customer Type	December 31, 2022		December 31, 2021
Diagnostic services	$	108,329	$	68,559
Contract manufacturing	8,740		5,786
Retail and others	1,281		2,454
Genomic products and services	4,297		2,243
Total revenue, net	$	122,647	$	79,042

Material Impacts of Adopting ASU

The following tables present the material impacts of adopting ASU No. 2021-08 on the Company’s consolidated balance sheets as of December 31, 2021 (in thousands):

	As of December, 31 2021
	Excluding impacts of adoption of ASU 2021-08		Adjustment		Presentation with adoption of ASU 2021-08
Assets
Goodwill	$	4,458	$	1,251	$	5,709
Liabilities
Deferred Revenue	$	2,655	$	284	$	2,939
Stockholders’ equity
Retained earnings	$	1,675	$	967	$	2,642

The following tables present the material impacts of adoption of ASU No. 2021-08 on the Company’s consolidated statements of operations for the year ended December 31, 2021 (in thousands):

	As of December, 31 2021
	Excluding impacts of adoption of ASU 2021-08		Adjustment		Presentation with adoption of ASU 2021-08
Revenue	$	78,075	$	967	$	79,042
Net income	$	5,306	$	967	$	6,273
Comprehensive income	$	5,142	$	967	$	6,109